Key-figures

Find out why Vetbiobank is leading the market with a few key figures.

Vetbiobank

• Registered sales in 4 European countries
• More than 500 treated animals
• A multidisciplinary team made of Doctors in Veterinary Medicine, Doctors in Pharmacy and Doctors in Cellular Biology
• 1 Doctorate of Science student et 4 veterinary theses underway
• 15 years of expertise of the value chain from donor to patient

A remarkable number of studies for a young research team.

• 5 clinical studies that are underway or completed.
• 2 published articles presenting our experimental studies results in international peer-reviewed journals (Impact factor : respectively 4,175 and 1,535)
• 1 article on mesenchymal stem-cells (MSC) and arthrosis in horses has been published with Pr. Olivier Lepage (Clinéquine – VetAgro Sup)
• 3 other articles are being written to be published in 2016.

Treated horses

• • • 80% of treated horses have gone back to competing, amongst which 80% have shown similar or superior results.
    • Only 23% of horses that were treated for tendinitis have relapsed (against 50 to 60% with classic treatments)
    • 5 M€ in winnings accumulated since 2012 by treated horses
    • 80% of client-recurrence, showcasing product and service satisfaction.
    • Vetbiobank collaborates with major Thoroughbred and Trotteurs-Français studfarms (see our references)

Treated dogs

• • • 60 and 70% of arthritic dogs (respectively elbow and hip) see their clinical scores improved by one or two levels up to six months following treatment and recover satisfying mobility.